• Plenaris Exosome HGF Hair Regeneration Treatment 5 Sessions
  • Plenaris Exosome HGF
  • Plenaris Exosome HGF
  • Plenaris Exosome HGF
  • Plenaris Exosome HGF
  • Plenaris Exosome HGF
  • Plenaris Exosome HGF
1 7

Nexus Pharma

Plenaris Exosome HGF Hair Regeneration Treatment 5 Sessions

Plenaris Exosome HGF Hair Regeneration Treatment 5 Sessions

$550.00 SGD
$550.00 SGD
促销 售罄
结账时计算的运费。
AI Summary: Plenaris Exosome HGF Hair Regeneration Treatment is a 5-session scalp injection protocol delivering exosome-encapsulated Hepatocyte Growth Factor (HGF) to stimulate follicular neovascularisation and extend the anagen (growth) phase. Each session delivers lyophilised exosome concentrate (≥1×10⁹ particles/mL, reconstituted) targeting dermal papilla cells via microinjection or microneedling-assisted transdermal delivery. HGF binds MET receptor tyrosine kinase on follicular stem cells, upregulating proliferative signalling cascades documented in androgenetic alopecia, telogen effluvium, and post-chemotherapy alopecia. The 5-session protocol is spaced at 2–4 week intervals. Manufactured under ISO 13485:2016 and ISO 9001:2015 quality frameworks. Distributed in Singapore by Essential Medical International Supplies Pte Ltd.

Plenaris Exosome HGF Hair Regeneration Treatment (5 Sessions) represents a next-generation biologics-derived approach to hair restoration, leveraging Hepatocyte Growth Factor (HGF) delivered via exosome vesicle technology for superior cellular uptake and sustained follicular stimulation versus conventional growth-factor injectables.

Technical Specifications

Parameter Specification
Active Biologic Hepatocyte Growth Factor (HGF) in exosome carrier
Exosome Concentration ≥1×10⁹ particles/mL (post-reconstitution)
Number of Sessions 5 sessions (complete protocol)
Session Interval 2–4 weeks between sessions
Delivery Method Scalp microinjection or microneedling-assisted transdermal
Molecular Target MET receptor tyrosine kinase on dermal papilla cells
Indications Androgenetic alopecia, telogen effluvium, post-chemotherapy alopecia, traction alopecia
Formulation Type Lyophilised exosome concentrate; single-use reconstituted vial per session
Storage −20°C (lyophilised); use within 4 hours post-reconstitution
Quality Standards ISO 13485:2016, ISO 9001:2015
Administration Clinic-administered by trained medical aesthetics practitioner

Clinical Q&A

Q: What is the mechanism of action of HGF in hair follicle regeneration?
A: HGF binds the MET proto-oncogene receptor tyrosine kinase expressed on dermal papilla cells and follicular keratinocytes. Receptor activation triggers downstream PI3K/AKT and RAS/MAPK signalling cascades that promote follicular cell proliferation, suppress apoptosis, and stimulate VEGF-mediated perifollicular angiogenesis. This extends the anagen (active growth) phase and promotes transition of miniaturised vellus follicles toward terminal hair production in androgenetic alopecia.

Q: Why is exosome encapsulation superior to free HGF injection for hair treatment?
A: Free HGF has a short plasma half-life (~3–5 minutes) due to rapid enzymatic degradation. Exosome encapsulation protects HGF from extracellular proteases, prolongs local bioavailability at the dermal papilla level, and enables endosomal uptake by target cells — delivering the growth factor intracellularly where it can directly interact with cytoplasmic signalling proteins. Exosomes also carry co-regulatory microRNAs that modulate follicular gene expression.

Q: How many sessions are required and what is the recommended treatment interval?
A: The complete Plenaris protocol comprises 5 sessions spaced 2–4 weeks apart (approximately 3–4 months total). Clinical assessment of treatment response — including dermoscopic evaluation of follicular density and hair shaft calibre — is recommended at session 3 to confirm anagen induction before completing the protocol.

Q: Which alopecia subtypes respond best to Plenaris Exosome HGF treatment?
A: Greatest clinical evidence exists for androgenetic alopecia (AGA, Hamilton-Norwood Stages I–IV) and telogen effluvium. Post-chemotherapy alopecia and traction alopecia also show favourable responses given intact follicular stem cell populations. Cicatricial (scarring) alopecias are typically poor candidates due to irreversible follicular destruction.

Q: What quality and regulatory standards govern the Plenaris Exosome HGF product?
A: Plenaris Exosome HGF is manufactured under ISO 13485:2016 (medical devices quality management) and ISO 9001:2015 frameworks. In Singapore, exosome-based biologics for aesthetic use fall under HSA's oversight of cell, tissue, and gene therapy products (CTGTPs) or as unregistered health products; practitioners should confirm current HSA classification status and applicable clinic licensing requirements before administering.

Regulatory & Standards References

  • ISO 13485:2016 — Medical devices quality management system; manufacturing framework for Plenaris Exosome HGF
  • ISO 9001:2015 — Quality management system standard applied to production facility
  • HSA Singapore — Health Sciences Authority oversight of cell, tissue and gene therapy products (CTGTPs); practitioners must verify current regulatory classification
  • ICH Q5C — Stability testing of biotechnological/biological products; applicable to lyophilised exosome formulation storage and handling
查看完整详细信息